Should perioperative apalutamide + ADT become the new standard for all patients with high-risk localized prostate cancer undergoing radical prostatectomy? ##Reference## Taplin M-E, Gleave M, Shore ND, et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med. 2026;395:546–560.

DOI: 10.1056/NEJMoa2603878## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including content from our industry partners. We do not associate with the views of any individual, community, organization, industry partner, or political party. Unauthorized use, reproduction, or…